If You Invested in Tff Pharmaceuticals, Inc. (TFFP)

TFF Pharmaceuticals, Inc. (TFFP) is described as a clinical-stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. According to company disclosures, the business is centered on transforming medicines into dry powder formulations that are intended to improve efficacy, safety, and stability, with particular emphasis on pulmonary and other targeted delivery routes.

In public statements, TFF Pharmaceuticals has indicated that it is a clinical-stage company, meaning its product candidates are undergoing clinical and preclinical evaluation rather than being approved commercial products. The company has reported work on inhaled dry powder formulations and has characterized its TFF platform as a particle engineering process designed to generate dry powder particles with properties suitable for inhalation, as well as for parenteral, nasal, oral, topical and ocular administration.

Business focus and technology platform

The company states that its proprietary Thin Film Freezing technology allows the transformation of both existing compounds and new chemical entities into dry powder formulations that exhibit specific characteristics. These include powders designed for direct delivery to the organ or tissue of interest, such as the lung, with the goal of improving bioavailability, onset of action, and safety profiles compared with conventional systemic administration.

Public materials from TFF Pharmaceuticals describe the TFF process as avoiding heat, shear stress, and other forces that can damage complex therapeutic components, including biologics. By rapidly freezing and drying formulations, the platform is presented as enabling temperature-stable dry powders that can be stored and distributed without the same constraints as many liquid formulations. The company has highlighted potential applicability to vaccines, small and large molecules, and biologics, and has described its powders as suited for inhalation or topical delivery to the eyes, nose, and skin.

Product candidates and development programs

Based on company communications and prior descriptions, TFF Pharmaceuticals has referenced multiple product candidates and programs built on its Thin Film Freezing platform. Earlier descriptions identify two lead drug candidates: voriconazole inhalation powder and tacrolimus inhalation powder (TFF TAC). The company has also reported work on vaccine and antiviral programs, including dry powder influenza vaccine candidates and collaborations involving mRNA-based antiviral approaches, all using the same underlying TFF technology to create inhalable or intranasal dry powders.

In more detailed updates, TFF Pharmaceuticals has described TFF TAC as an inhaled dry powder formulation of tacrolimus, a potent immunosuppressive drug that is widely used in oral form for prevention of rejection after solid organ transplantation. Company materials explain that oral tacrolimus is associated with toxicities such as kidney toxicity, particularly at higher doses. TFF TAC is described as designed to deliver tacrolimus directly to the lung to seek improved lung immunosuppression at lower systemic exposure compared with oral tacrolimus. The company has reported an ongoing Phase 2 trial of TFF TAC in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity, with endpoints including safety, tolerability, kidney function, acute allograft rejection, and pharmacokinetics.

In addition to tacrolimus, TFF Pharmaceuticals has publicly discussed TFF-formulated vaccine candidates, including bivalent or multivalent universal influenza vaccine candidates manufactured using the TFF process for intranasal delivery. The company has reported preclinical data in ferret models showing neutralizing antibody titers against specific influenza strains after intranasal administration of TFF-dry powder hemagglutinin antigen vaccine candidates.

Thin Film Freezing technology characteristics

Across multiple disclosures, TFF Pharmaceuticals emphasizes several recurring characteristics of its Thin Film Freezing technology:

• The process is described as a particle engineering method that generates dry powder particles with aerodynamic properties considered advantageous for inhalation.
• Company materials state that laboratory data suggest powders created by TFF can deliver a substantial portion of the dose to the deep lung, and that the powders can disaggregate rapidly into smaller particles once administered.
• The TFF process is said to avoid heat and shear forces, which the company notes can be important for maintaining the integrity of fragile biologics and complex therapeutic molecules.
• The resulting powders are described as temperature-stable and suitable for storage and distribution without the same cold-chain requirements as many liquid formulations, which the company positions as beneficial for broader access and logistics.

TFF Pharmaceuticals has also described its platform as versatile, with potential use across multiple routes of administration beyond inhalation, including parenteral, nasal, oral, topical, and ocular delivery, and has stated that it can be applied to both existing drugs and new chemical entities.

Collaborations and research relationships

Public announcements from TFF Pharmaceuticals describe collaborations with academic institutions and government-related entities. Examples include work with Emory University and the Biomedical Advanced Research and Development Authority (BARDA) to test the feasibility of converting an mRNA-based Cas13a antiviral into a dry powder formulation for inhalational delivery, and collaborations with Cleveland Clinic on universal influenza vaccine candidates formulated using TFF technology. The company has also referenced funded research programs supported by U.S. government agencies such as BARDA and the National Institute of Allergy and Infectious Diseases.

In addition, TFF Pharmaceuticals has described engagements with organizations such as Outcome Capital to evaluate potential corporate partnerships and licensing opportunities for its TFF-based clinical assets. These disclosures indicate that, alongside internal development, the company has sought to position its TFF platform for partnering and out-licensing arrangements.

Corporate status and planned wind-down

More recent company announcements provide important context on TFF Pharmaceuticals’ corporate status. In a disclosure dated November 14, 2024, the company announced that it had terminated its employees and would wind down its operations, following a decision made at a special meeting of the board of directors. In that same announcement, the board appointed an executive with experience in distressed businesses and corporate wind-downs as the company’s CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board, with a mandate focused on managing the wind-down phase.

Subsequently, in a February 6, 2025 announcement, TFF Pharmaceuticals stated that it had notified The Nasdaq Stock Market of its intent to voluntarily delist its common stock from the Nasdaq Capital Market. The company indicated that it expected to file a Form 25 (Notification of Removal from Listing) with the U.S. Securities and Exchange Commission and Nasdaq, and that removal of the common stock from Nasdaq would become effective 10 days after that filing. The same announcement stated that the company had made no arrangements for listing or quotation of its common stock on any other exchange, market, or quotation medium, and that the withdrawal from listing and registration was being undertaken in connection with the planned liquidation and dissolution of the company.

These disclosures indicate that TFF Pharmaceuticals has moved from an active clinical-stage development posture toward a wind-down, liquidation, and dissolution process, and that its Nasdaq listing is in the process of being voluntarily removed. The company’s own statements link the delisting and deregistration steps to this planned liquidation and dissolution.

Position within the pharmaceutical manufacturing sector

Within the broader category of pharmaceutical preparation manufacturing, TFF Pharmaceuticals has presented itself as focused on formulation science and drug delivery rather than on discovery of entirely new molecular entities. Its emphasis on Thin Film Freezing as a platform for converting existing and novel compounds into dry powder formulations places the company in a niche that intersects inhalation technology, vaccine and antiviral formulation, and targeted organ delivery.

Company communications repeatedly describe the TFF platform as applicable to vaccines, small molecules, large molecules, and biologics, and as enabling direct delivery to organs such as the lung, as well as topical delivery to the eyes, nose, and skin. This positioning suggests that, during its operating phase, TFF Pharmaceuticals sought to create value both through proprietary product candidates like TFF TAC and through potential collaborations where its formulation technology could be applied to partners’ compounds.

FAQs about TFF Pharmaceuticals (TFFP)

The following questions and answers summarize key points drawn from the company’s own public disclosures and descriptions.